Quorn in Community Health Experiment

Overweight and Obesity Clinical Trial

— QUICHE  

Official title:

Quorn in Community Health Experiment

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04773483
• Other study ID #: 201021-B-02 Wall
• Status: Completed
• Phase: N/A
• Start date: November 9, 2020
• Est. completion date: December 17, 2021

Study information

• Verified date: March 2023
• Source: University of Exeter
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In overweight individuals (BMI > 27.5 kg/m2), does daily consumption of mycoprotein containing Quorn Food products lower blood cholesterol compared with daily meat/fish consumption?

Recruitment information / eligibility

• Status: Completed
• Enrollment: 82
• Est. completion date: December 17, 2021
• Est. primary completion date: December 17, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• 18-70 years old

• BMI >27.5 kg/m2

• Non allergic to penicillin/mycoprotein

• Moderate levels of physical activity or below (self-identified; NDNS servey)

• Omnivores

• Not currently using cholesterol lowering medication

Exclusion Criteria:

• <18 or >70 years old

• BMI <27.5 kg/m2

• Allergies to penicillin/mycoprotein

• Heavy exercisers (self idenfiied)

• Vegetarian/vegans

• Currently using cholesterol lowering medication

Related Conditions & MeSH terms

• Overweight
• Overweight and Obesity

Intervention

Dietary Supplement:
• Quorn Foods products
180 g mycoprotein (wet weight; corresponding to 45 g dry weight) per day (equates to approx. 215 g Quorn Foods products, depending on the product)
• Meat/fish products
Standard meat/fish products matched to Quorn group for protein intake

Locations

Country	Name	City	State
United Kingdom	University of Exeter	Exeter	Devon

Sponsors (3)

Lead Sponsor	Collaborator
University of Exeter	Marlow Foods Ltd, NIHR Exeter Clinical Research Facility

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Postabsorptive blood cholesterol (free, total, LDL, HDL) concentrations	Test for intervention vs control differences in postabsorptive blood cholesterol levels (mMol) pre and post intervention	4 weeks
Secondary	Postprandial blood cholesterol concentration	Test for intervention vs control differences in postprandial blood cholesterol levels (mMol) pre and post intervention	3 hours
Secondary	Fingerprick blood glucose concentration	Test for intervention vs control differences in blood glucose concentration (mMol) in postabsorptive and postprandial state	4 weeks
Secondary	Satiety	Test for intervention vs control differences in satiety using a 10 centimetre 'Satiety Visual Analogue Scale' ratings, anchored by minimum to maximum response for a given aspect of satiety, where 0 cm is minimum and 10 cm is maximum	4 weeks
Secondary	Hedonic visual analogue scale	Test for intervention vs control differences and changes in hedonic response using 10 cm 'Hedonic Visual Analogue Scale' ratings, anchored by minimum to maximum response for a given aspect of hedonic response, where 0 cm is minimum and 10 cm is maximum	4 weeks
Secondary	Gastrointestinal side-effects	Test for intervention vs control differences in tolerance of diet	Once weekly, over 4 weeks
Secondary	Fingerprick blood c-peptide	Test for intervention vs control differences in C-peptide concentration (ng/ml) in postabsorptive and postprandial state	4 weeks
Secondary	Fingerprick blood triglyceride concentration	Test for intervention vs control differences in blood triglyceride concentration (mMol) in postabsorptive and postprandial state	4 weeks